Selective Coronary Revascularization in Peripheral Artery Disease Patients (SCOREPAD Trial)

Recruiting now

Conditions studied: Peripheral Arterial Disease, Coronary Artery Disease

In brief

The primary objective of this study is to determine whether among symptomatic Peripheral Arterial Disease (PAD) patients with no known Coronary Artery Disease (CAD) who had undergone lower-extremity revascularization, a strategy of best medical therapy (BMT) plus selective coronary revascularization based on FFRct assessment of lesion-specific coronary ischemia can reduce adverse cardiac events and improve survival compared to BMT alone. Lesion-specific coronary ischemia is defined as FFRCT ≤0.80 distal to stenosis in a major (≥2 mm) coronary artery with severe ischemia defined as FFRCT ≤0.75.

Key facts

Study ID

NCT06250790

Run by

Pauls Stradins Clinical University Hospital

People needed

600

Starts

2024-02-15

Expected to finish

2029-02-15

Last updated by the study team

2024-02-16

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Inform consent obtained before any study-related activities;
• Age above or equal to 50 years with symptomatic lower extremity PAD (severe claudication or chronic limb-threatening ischemia, Rutherford 3,4,5) which has been successfully revascularized by open surgical or endovascular procedure within the past 14 days;
• Willing and able to undergo coronary CTA scan within 14 days of randomization and agrees to submission of CTA data set for HeartFlow FFRct analysis with results made available to treating physician.

You may not qualify if…

• Known CAD, history of MI, prior coronary revascularization (PCI or CABG);
• Patient underwent coronary angiography or coronary CTA before the randomization;
• Known history of 2nd or 3rd degree heart block; sick sinus syndrome; long QT syndrome;
• History of severe asthma, severe or bronchodilator-dependent Chronic obstructive pulmonary disease (COPD);
• Severe congestive heart failure (NYHA III or IV);
• Severe arrhythmia, prior pacemaker or internal defibrillator lead implantation;
• Impaired chronic renal function (EPI-Glomerular Filtration Rate (GFR)<30ml/min);
• Subjects with known anaphylactic allergy to iodinated contrast;
• Pregnancy or unknown pregnancy status in subject of childbearing potential;
• Evidence of ongoing or active clinical instability, including acute chest pain (sudden onset), cardiogenic shock, unstable blood pressure with systolic blood pressure <90 mmHg, or acute pulmonary edema;
• Any active, serious, life-threatening disease with a life expectancy of less than 2 years;
• Any active infection;
• Inability to comply with study procedures;
• Contraindication for guideline-guided longterm antiplatelet/anticoagulation regime after PCI/CABG;
• Participation in any interventional clinical study within 30 days prior to screening.

Where it is running

• Pauls Stradins Clinical University hospital — Riga, Latvia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.